The following is a complete listing of all claims in the application, with an indication of the status of each:

## Listing of claims:

Claims 1-22. (Cancelled).

23. (Previously presented) A method of administering a pharmaceutically effective dose of aerosolized tetrahydrocannabinol to a patient, comprising the steps of:

providing a solution comprising a pharmaceutically acceptable form of said tetrahydrocannabinol in a hydrofluoroalkane, said solution having not more than 15% of a pharmaceutically acceptable solvent;

aerosolizing said solution to provide respirable droplets comprising said tetrahydrocannabinol, wherein at least 20% of the mass of said respirable droplets comprise droplets having an aerodynamic diameter of less than  $5.8~\mu m$ ;

administering a pharmaceutically effective dose of said respirable droplets to said patient's lungs.

- 24. (Previously presented) The method of claim 23 wherein said tetrahydrocannabinol is present in pharmaceutically pure form.
- 25. (Previously presented) The method of claim 23 wherein said tetrahydrocannabinol is a pharmaceutically acceptable salt of said tetrahydrocannabinol.
- 26. (Previously presented) The method of claim 23 wherein said pharmaceutically acceptable solvent comprises ethanol.
- 27. (Previously presented) The method of claim 23 wherein said solution consists essentially of said hydrofluoroalkane and said tetrahydrocannabinol.
- 28. (Previously presented) The method of claim 23 wherein said solution is surfactant free.

- 29. (Previously presented) The method of claim 23 wherein said tetrahydrocannabinol is present in said solution at a concentration sufficient to achieve serum concentration levels in said patient of 10-100 ng/ml fifteen minutes following inhalation.
- 30. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to treat nausea.
- 31. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to treat vomiting.
- 32. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to reduce pain.
- 33. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to relieve muscle spasticity.
- 34. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to relieve migraine headaches.
- 35. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to relieve movement disorders.
- 36. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to increase appetite in patients suffering from cachexia.
- 37. (Previously presented) A method of administering a pharmaceutically effective dose of medical marijuana to a patient, comprising the steps of:

providing a solution comprising a pharmaceutically acceptable form of said medical

marijuana in a hydrofluoroalkane, said solution having not more than 15% of a pharmaceutically acceptable solvent;

aerosolizing said solution to provide respirable droplets comprising said medical marijuana, wherein at least 20% of the mass of the respirable droplets comprise droplets having an aerodynamic diameter of less than 5.8  $\mu m$ ;

administering a pharmaceutically effective dose of said respirable droplets to said patient's lungs.

- 38. (Previously presented) The method of claim 37 wherein said pharmaceutically acceptable solvent comprises ethanol.
- 39. (Previously presented) The method of claim 37 wherein said solution consists essentially of said hydrofluoroalkane and said medical marijuana.
- 40. (Previously presented) The method of claim 37 wherein said solution is surfactant free.
- 41. (Previously presented) The method of claim 37 wherein said medical marijuana is present in said solution at a concentration sufficient to achieve serum concentration levels in said patient of 10-100 ng/ml fifteen minutes following inhalation.
- 42. (Previously presented) The method of claim 37 wherein said pharmaceutically effective dose is sufficient to treat a condition selected from the group consisting of nausea, vomiting, pain, muscle spasticity, migraine headaches, movement disorders, and loss of appetite due to cachexia.
- 43.(Previously presented) A pharmaceutical composition comprising a hydrofluoroalkane,  $\Delta^9$ -tetrahydrocannabinol, and up to 15 percent by weight of an organic solvent, said  $\Delta^9$ -tetrahydrocannabinol and said organic solvent being dissolved in said hydrofluoroalkane to form a stable composition, wherein said  $\Delta^9$ -tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w ( $\pm 0.008$ ) to 5.940% w/w ( $\pm 0.191$ ).

- 44. (Previously presented) The pharmaceutical composition of claim 43 wherein said  $\Delta^9$ -tetrahydrocannabinol is present in pharmaceutically pure form.
- 45. (Previously presented) The method of claim 43 wherein said  $\Delta^9$ -tetrahydrocannabinol is a pharmaceutically acceptable salt of said  $\Delta^9$ -tetrahydrocannabinol.
- 46. (Previously presented) The pharmaceutical composition of claim 43 wherein said organic solvent comprises ethanol.
- 47. (Previously presented) The pharmaceutical composition of claim 43 wherein said solution consists essentially of said hydrofluoroalkane and said  $\Delta^9$ -tetrahydrocannabinol.
- 48. (Previously presented) The pharmaceutical composition of claim 43 wherein said stable composition is surfactant free.
- 49. (Previously presented) The pharmaceutical composition of claim 43 wherein said  $\Delta^9$ tetrahydrocannabniol is present in said stable composition at a concentration sufficient to achieve
  serum concentration levels in a patient of 10-100 ng/ml fifteen minutes following inhalation.
- 50. (Previously presented) A pharmaceutical composition comprising a hydrofluoroalkane, a tetrahydrocannabinol, and up to 15 percent by weight of an organic solvent, said tetrahydrocannabinol and said organic solvent being dissolved in said hydrofluoroalkane to form a stable composition, wherein said tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w (±0.008) to 5.940% w/w (±0.191).
- 51. (Previously presented) The pharmaceutical composition of claim 50 wherein said tetrahydrocannabinol is present in pharmaceutically pure form.

- 52. (Previously presented) The method of claim 50 wherein said tetrahydrocannabinol is a pharmaceutically acceptable salt of said tetrahydrocannabinol.
- 53. (Previously presented) The pharmaceutical composition of claim 50 wherein said organic solvent comprises ethanol.
- 54. (Previously presented) The pharmaceutical composition of claim 50 wherein said solution consists essentially of said hydrofluoroalkane and said tetrahydrocannabinol.
- 55. (Previously presented) The pharmaceutical composition of claim 50 wherein said stable composition is surfactant free.
- 56. (Previously presented) The pharmaceutical composition of claim 50 wherein said tetrahydrocannabinol is present in said stable composition at a concentration sufficient to achieve serum concentration levels in a patient of 10-100 ng/ml fifteen minutes following inhalation.